Clinical Trial Update: Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing the efficacy and safety of ustekinumab in patients with Behçet disease has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Behçet Disease

Drugs mentioned

• Stelara (ustekinumab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Behçet Disease | Phase 2 | Status: COMPLETED